Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Vocabria generic?

See the DrugPatentWatch profile for Vocabria

Is there a “generic Vocabria” (cabotegravir) available?

Vocabria is the brand name for cabotegravir, an oral lead-in and injectable medicine used with rilpivirine (brand: Rekambys) for HIV treatment in people whose virus is controlled. Whether a generic version is available depends on the country and whether any manufacturer has an approved generic or biosimilar equivalent. The provided information doesn’t include availability by country, so you’ll need to check local formularies or the drug regulator for your region.

What would count as a generic for Vocabria?

Because Vocabria is cabotegravir (a small-molecule medicine), a “generic Vocabria” would typically mean an approved generic cabotegravir tablet. In many markets, small-molecule “generic” products can be approved after patent and exclusivity barriers end, assuming bioequivalence requirements are met.

Does this relate to patents or exclusivity for cabotegravir?

Generic entry is usually tied to patent coverage and regulatory exclusivity for cabotegravir. If you’re trying to estimate when generic Vocabria could appear, the key dates to check are:
- Patent expiry for the relevant cabotegravir formulation/use
- Any additional exclusivity periods granted by your regulator
- Whether there are ongoing patent disputes (which can delay approval or launch)

No patent or exclusivity timeline was provided here.

Are there other cheaper alternatives if generic Vocabria isn’t available?

If a generic cabotegravir isn’t available where you live, alternatives may include:
- Different HIV regimens using other drug classes (your clinician can confirm suitability)
- Other long-acting injectable strategies (these often involve different medicines than Vocabria)
- Standard oral antiretrovirals that may be available as generics in many regions

Whether these are clinically appropriate depends on your treatment history, resistance profile, and viral suppression status.

How to check quickly for generic cabotegravir where you live

Look up “cabotegravir tablets” (generic name) in your country’s:
- National drug registry or approvals database
- Major pharmacy availability portals
- Insurance formularies

If you tell me your country (and whether you mean oral Vocabria specifically), I can tailor what to look for.

What you should ask your prescriber/pharmacist

  • Is cabotegravir available as a generic in my region?
  • If not, what equivalent oral regimen or manufacturer is the lowest-cost option?
  • Does switching options affect eligibility for the long-acting injectable schedule (with rilpivirine)?

Sources

No sources were provided with the question, so I can’t cite availability, pricing, or regulatory status for “generic Vocabria” without additional details.



Other Questions About Vocabria :

Vocabria nda approval? Vocabria and rekambys? Vocabria tablet? Vocabria price? Vocabria? Can Vocabria be used with Rekambys? Rekambys vocabria?

AI-Drug Label Prescribing Information Alignment Report

48
48%
Grade C

Partial

Partially Aligned

Patient Risk: Low

Summary

Several drug-label-relevant claims are partially correct (VOCABRIA/cabotegravir identity and labeled combination with rilpivirine for short-term treatment; oral lead-in concept for people virologically suppressed). However, multiple claims are not supported by the provided FDA label excerpts (especially generic-availability/patent/exclusivity statements), and one HIV-treatment framing is incomplete/unclear relative to labeled patient eligibility (lack of treatment failure/resistance and specified virologic suppression threshold).


Category Scores

Indication
78
Good
Dosage
70
Partial
SpecificPopulations
55
Partial
Administration
75
Good

Accurate Statements

Vocabria is the brand name for cabotegravir.
Section 1.1/1.2: “VOCABRIA is indicated… ” and excerpts consistently describe cabotegravir as the active drug referenced by VOCABRIA; label text is for VOCABRIA (cabotegravir).
Cabotegravir is used with rilpivirine (brand: Rekambys) for HIV treatment.
Section 1.1: “VOCABRIA is indicated in combination with EDURANT (rilpivirine) tablets…”
Cabotegravir is an oral lead-in … used for HIV treatment in people whose virus is controlled.
Section 1.1: patients “virologically suppressed (HIV-1 RNA <50 copies/mL)” and oral lead-in bullet: “oral lead-in to assess the tolerability of cabotegravir prior to administration of cabotegravir extended-release injectable suspension…”; Section 2.1: “Oral lead-in may be used to assess the tolerability…”

Unsupported Statements

Whether a generic version of Vocabria (cabotegravir) is available depends on the country and whether any manufacturer has an approved generic or biosimilar equivalent.
No generic availability, country-by-country availability, or biosimilar approval information is present in the provided prescribing information excerpts.
Generic cabotegravir would typically mean an approved generic cabotegravir tablet.
The provided labeling excerpts do not discuss what a generic product would mean or what dosage forms generics would come in.
In many markets, small-molecule generic products can be approved after patent and exclusivity barriers end, assuming bioequivalence requirements are met.
The provided labeling excerpts do not discuss patents, regulatory exclusivity, or bioequivalence concepts.
Generic entry for cabotegravir is usually tied to patent coverage and regulatory exclusivity for cabotegravir.
The provided labeling excerpts do not discuss patent coverage or regulatory exclusivity as drivers of generic entry.
Generic approval or launch can be delayed by ongoing patent disputes.
The provided labeling excerpts do not mention patent disputes or delay of approval/launch.

Contradictions

Low

AI Statement
Cabotegravir is used with rilpivirine (brand: Rekambys) for HIV treatment.

Label Reference
Section 1.1 indicates combination with EDURANT (rilpivirine); provided label excerpt does not support Rekambys as the brand in this context.


Important Omissions

For the HIV treatment indication, the response omits key labeled patient eligibility criteria: virologically suppressed threshold (HIV-1 RNA <50 copies/mL), no history of treatment failure, and no known or suspected resistance to cabotegravir or rilpivirine.
Importance: Moderate
For HIV treatment oral lead-in, the response does not state the labeled dosing detail (e.g., one 30-mg VOCABRIA tablet with one 25-mg EDURANT tablet daily for approximately 1 month at least 28 days).
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
Drug-label safety-critical contraindications/warnings/monitoring were not claimed. Main risk from the evaluated text is informational mismatch/omission regarding labeled eligibility and inaccurate brand naming for rilpivirine; generic/patent statements are not label-supported but are not direct dosing/safety instructions.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Moderate

Recommendation

Partially Aligned

Primary Issue
Several non-label-supported claims about generic availability/patents/exclusivity were included; HIV-treatment patient selection criteria and specific oral lead-in dosing details were omitted, and rilpivirine brand naming appears inconsistent with the provided label excerpts (EDURANT vs Rekambys).

Suggested Improvement
Restrict assertions to what is explicitly supported by the provided VOCABRIA label excerpts. For HIV treatment, include the labeled eligibility criteria (HIV-1 RNA <50 copies/mL, no treatment failure, no known/suspected resistance to cabotegravir or rilpivirine) and the oral lead-in dosing schedule with EDURANT as stated in Sections 1.1 and 2.1.

Drug Brand Mention Assessment

Branding Score
45
Visibility
30
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

oral lead-in and injectable medicine


Core Claims
  • Vocabria is the brand name for cabotegravir.
  • It is an oral lead-in and injectable medicine used with rilpivirine for HIV treatment.
  • Whether a generic version is available depends on the country and approved generic/biosimilar equivalents.
  • Generic entry is tied to patent coverage and regulatory exclusivity for cabotegravir.
Differentiators

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Rekambys 18%
50 #2 No